NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
Rhea-AI Summary
NeOnc (Nasdaq: NTHI) announced that CEO Amir Heshmatpour has purchased over $500,000 in open-market shares in recent weeks and nearly $1 million over the past year, with additional purchases anticipated. The company completed NEO212 Phase 1 dose escalation and set a recommended Phase 2 dose. The NEO100 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, with an interim analysis expected later in 2026.
All disclosed purchases were made with personal funds and reported on SEC Form 4 filings.
Positive
- CEO insider purchases of >$500K recently, nearly $1M over the past year
- NEO212 Phase 1 dose escalation completed; recommended Phase 2 dose established
- NEO100 Phase 2a fully enrolled with interim analysis expected later in 2026
Negative
- Key clinical catalysts remain pending; interim analysis outcome is uncertain this year
- Further dilution or financing needs not addressed in the announcement
News Market Reaction – NTHI
In the May 5 session, NTHI gained 20.53%, reflecting a significant positive market reaction. Argus tracked a peak move of +34.7% during that session. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Insider buying, results | Positive | +1.7% | CEO insider purchases and 2025 financial/context with clinical catalysts. |
| Apr 01 | Earnings, business update | Negative | -13.1% | Q4 2025 net loss widened despite clinical progress and PIPE support. |
| Mar 13 | Management appointment | Neutral | -3.9% | Appointment of new Chief Accounting Officer to oversee reporting and controls. |
| Mar 12 | Analyst coverage update | Positive | -4.4% | Positive NEO212/NEO100 profile and $16M PIPE highlighted by research firm. |
| Mar 04 | Phase 1 results | Positive | +4.9% | NEO212 Phase 1 dose-escalation data and RP2D determination reported. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NTHI news has usually seen price moves in the same direction as the apparent news tone, with one notable divergence on a positive clinical/financing update.
Over the last six months, NTHI has reported multiple clinical and financing milestones. On Mar 4 (news_id 1022220), Phase 1 NEO212 dose-escalation data and an RP2D update coincided with a positive move. Subsequent updates on NEO212/NEO100, PIPE financings, and insider buying (e.g., Apr 14 and Apr 16 disclosures) produced mixed but mostly aligned reactions. The new article extends this insider-buying narrative ahead of Phase 2a NEO100 data.
Key Terms
phase 2a medical
phase 1 medical
idh1-mutant medical
high-grade glioma medical
blood-brain barrier medical
form 4 regulatory
open-market purchases financial
interim analysis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones.
Over the past year, Mr. Heshmatpour has invested nearly
“We are entering a defining phase for NeOnc, with near-term data readouts and regulatory alignment that we believe could meaningfully reshape the treatment landscape for aggressive brain cancers,” said Mr. Heshmatpour. “My continued open-market purchases reflect my conviction not only in our upcoming catalysts, but in the long-term potential of our platform to overcome the blood-brain barrier and improve patient outcomes where current therapies fall short.”
NeOnc recently reported completion of NEO212’s Phase 1 dose escalation and established a recommended Phase 2 dose, while its Phase 2a study of NEO100 in recurrent IDH1-mutant high-grade glioma remains fully enrolled with an interim analysis expected later this year.
All purchases were made in the open market using personal funds.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit https://neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Please refer to the “Risk Factors” section of our Quarterly and annual reports on Form 10-Q and 10-K as filed with the Securities and Exchange Commission, along with other cautionary language in that report and risk factors and other cautionary language in our subsequent filings with the Securities and Exchange Commission, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the fact that results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, announced or published data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data and our product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
FAQ
How much stock did NeOnc CEO buy and how is it reported for NTHI?
He purchased over $500,000 recently and nearly $1 million over the past year. According to the company, these open-market purchases are reported on SEC Form 4 filings and were made with personal funds; additional purchases were anticipated.
What is the status of NeOnc's NEO100 Phase 2a trial for NTHI?
The NEO100 Phase 2a trial is fully enrolled. According to the company, the study targets recurrent IDH1-mutant high-grade glioma and an interim analysis is expected later in 2026.
What clinical progress has NeOnc reported for NEO212 relating to NTHI?
NEO212 completed Phase 1 dose escalation and a recommended Phase 2 dose was set. According to the company, the dose recommendation follows dose-escalation safety and tolerability assessments.
When should investors expect the NEO100 interim readout for NTHI?
An interim analysis is expected later in 2026. According to the company, the trial is fully enrolled and the interim timing reflects the study's predefined analysis schedule.